Greece Cannabis Retail Ban: Policy, Impact, and Legal Framework

Executive Summary

Greece has banned the retail sale of cannabis-based products effective May 2026, marking a significant reversal in the country's approach to hemp-derived cannabinoid commerce. The prohibition targets products containing CBD, THCA, and other cannabinoids that had been sold in specialty shops, pharmacies, and general retail outlets across Greece since the European Union's broader hemp liberalization. The ban affects an estimated 2,000-3,000 retail locations nationwide and eliminates a market segment valued at approximately €150-200 million annually. Greek authorities cite public health concerns and regulatory gaps as justification, though industry advocates argue the move contradicts EU single market principles and damages legitimate businesses that invested heavily in compliance infrastructure. The prohibition does not affect Greece's medical cannabis program, which operates under separate pharmaceutical regulations, nor does it impact the country's agricultural hemp cultivation sector. However, the retail ban creates immediate uncertainty for manufacturers, distributors, and retailers who built operations around legal cannabinoid commerce, and raises questions about Greece's commitment to harmonizing with broader European cannabis policy trends.

Why This Matters

The Greek retail ban affects thousands of business owners, hundreds of thousands of consumers, and tests the boundaries of EU regulatory harmonization in cannabis policy. The prohibition immediately impacts approximately 2,000-3,000 retail establishments across Greece that had been selling CBD oils, hemp flower, THCA products, and other cannabinoid-containing items. These range from dedicated hemp shops in Athens and Thessaloniki to pharmacies in smaller cities and tourist-oriented retailers on islands like Mykonos and Santorini. Industry estimates suggest the sector employed 5,000-8,000 people directly, with another 10,000-15,000 jobs in cultivation, processing, and distribution facing uncertainty. Greek consumers who had integrated CBD products into wellness routines—estimated at 300,000-500,000 regular users based on market research—now face restricted access. Many had used CBD oils for chronic pain management, anxiety relief, and sleep disorders, purchasing products legally from licensed retailers with third-party lab testing. The ban forces these consumers toward either medical cannabis pathways, which require physician authorization and are limited to specific conditions, or gray-market sources without quality controls. The economic impact extends beyond direct retail. Greece's agricultural hemp sector, which expanded significantly after EU regulations permitted cultivation of hemp varieties containing up to 0.3% THC, faces demand destruction. Farmers in regions like Thessaly and Macedonia who planted hemp specifically for the cannabinoid extraction market now lack domestic buyers, though export markets remain theoretically available. Investment capital that flowed into Greek cannabis businesses—estimated at €50-100 million between 2020 and 2025—faces potential write-downs. The ban also carries implications for EU regulatory coherence. Greece operates within the European single market, where goods legally sold in one member state generally enjoy free movement across borders. The retail prohibition creates potential conflicts with EU law, particularly if products manufactured in other member states and compliant with EU Novel Food regulations face exclusion from Greek commerce. Legal challenges appear likely, with industry groups already signaling intent to contest the ban through both Greek courts and EU mechanisms.

Background and History

Greece's cannabis retail market emerged from a complex interplay of EU hemp liberalization, domestic medical cannabis legalization, and entrepreneurial exploitation of regulatory gray zones.

Ancient and Modern Cannabis History in Greece

Cannabis has deep historical roots in Greece, with archaeological evidence suggesting use dating back to ancient times. However, modern prohibition began in the early 20th century, with Greece signing the 1925 International Opium Convention and subsequently criminalizing cannabis cultivation, possession, and sale. For decades, Greece maintained strict prohibition, with penalties including imprisonment for possession and cultivation. The first significant shift came in 2017, when Greece legalized medical cannabis cultivation and production under Law 4523/2018. This legislation, passed by the Syriza government, permitted licensed companies to grow cannabis for pharmaceutical purposes, positioning Greece as a potential Mediterranean cultivation hub with favorable climate and lower labor costs compared to Northern Europe. The law established a regulatory framework overseen by the Greek Medical Cannabis Organization, requiring cultivation licenses, security protocols, and pharmaceutical-grade processing standards.

EU Hemp Liberalization and the CBD Boom

The broader context for Greece's retail market emerged from EU-level developments. In 2020, the European Court of Justice ruled in the Kanavape case that CBD derived from legally grown hemp constitutes a legal product under EU law and cannot be prohibited by member states absent specific public health justifications. This decision accelerated CBD market growth across Europe, with products proliferating in health food stores, pharmacies, and specialty shops. Greece's retail cannabinoid market began expanding significantly in 2021-2022. Entrepreneurs opened dedicated hemp shops in major cities, selling CBD oils, hemp flower, edibles, and topicals. Many products were imported from other EU member states where manufacturing infrastructure was more developed, particularly the Netherlands, Switzerland, and Czech Republic. Greek manufacturers also emerged, processing domestically grown hemp into finished consumer products.

The THCA Loophole and Market Expansion

A particularly significant development came with the rise of THCA products in 2023-2024. THCA (tetrahydrocannabinolic acid) is the non-intoxicating precursor to THC found in raw cannabis. When heated through smoking or vaping, THCA converts to psychoactive THC, but in its raw form it remains non-intoxicating. Greek retailers began selling high-THCA hemp flower, marketed as legal because the products contained less than 0.3% THC in their raw state, complying with EU hemp definitions. This created a de facto legal cannabis market. Consumers could purchase products that, while technically compliant with hemp regulations, provided effects similar to traditional cannabis when consumed. Greek authorities initially tolerated this market, with no clear enforcement actions against retailers selling THCA products. The market expanded rapidly, with THCA flower becoming available in dozens of shops across Athens, Thessaloniki, and tourist destinations.

Regulatory Concerns and Government Response

By late 2024, Greek health authorities began expressing concerns about the cannabinoid retail market. The Hellenic National Organization for Medicines raised issues about product quality, labeling accuracy, and the lack of pharmaceutical oversight for products making health claims. Reports emerged of products with inaccurate cannabinoid content, contamination with pesticides, and misleading marketing claims. The Ministry of Health initiated consultations with industry stakeholders, law enforcement, and public health experts throughout late 2024 and early 2025. Industry representatives argued for a regulated framework rather than prohibition, proposing licensing requirements, testing standards, and marketing restrictions similar to those implemented in Switzerland and the Netherlands. However, conservative political factions and some medical associations advocated for stricter controls, arguing that the retail market had evolved beyond the intent of EU hemp regulations.

The May 2026 Ban

On May 16, 2026, the Greek government announced the retail ban through a ministerial decision issued by the Ministry of Health. The decision prohibits the sale of products containing CBD, THCA, and other cannabinoids through retail channels, effective immediately. The ban applies to physical retail locations, online sales to Greek consumers, and wholesale distribution to retailers. Existing inventory must be removed from shelves within 30 days, with no compensation mechanism announced for affected businesses. The government justified the ban on public health grounds, citing concerns about product safety, youth access, and the psychoactive potential of THCA products. Officials stated that cannabinoid products should be available only through medical cannabis pathways with physician oversight. The announcement provided no transition period for businesses to adjust operations or liquidate inventory at non-loss prices.

Key Players

Greek Ministry of Health

The Ministry of Health issued the retail ban and maintains primary regulatory authority over cannabinoid commerce in Greece. Minister of Health Adonis Georgiadis, representing the center-right New Democracy party, has consistently advocated for stricter cannabis controls. The Ministry's position emphasizes pharmaceutical oversight for all cannabinoid products, arguing that retail sales outside medical channels create public health risks. The Ministry coordinates with the Hellenic National Organization for Medicines on enforcement and has indicated that violations of the retail ban will result in fines and potential criminal charges for repeat offenders.

Hellenic National Organization for Medicines

The Hellenic National Organization for Medicines (EOF) oversees pharmaceutical product authorization in Greece. EOF has expressed concerns about cannabinoid retail products since 2023, publishing reports documenting quality control issues in market surveillance testing. According to EOF, approximately 30% of tested CBD products contained cannabinoid levels differing by more than 20% from label claims, and 15% showed pesticide contamination exceeding EU limits. EOF supports the retail ban while advocating for expanded medical cannabis access through regulated pharmaceutical channels.

Greek Cannabis Industry Association

The Greek Cannabis Industry Association represents approximately 150 businesses involved in cultivation, processing, and retail. The association has strongly opposed the retail ban, arguing it violates EU single market principles and destroys legitimate businesses without addressing underlying regulatory concerns. The association has announced plans to challenge the ban through Greek administrative courts and has requested European Commission intervention. Association president Dimitris Papadopoulos stated the ban eliminates €200 million in annual economic activity and forces thousands of job losses without evidence that regulated retail posed public health threats.

European Industrial Hemp Association

The European Industrial Hemp Association (EIHA), representing hemp businesses across the EU, has criticized Greece's retail ban as inconsistent with EU law. EIHA argues that products compliant with EU hemp regulations and Novel Food requirements cannot be prohibited by individual member states without specific, evidence-based public health justifications. The association has indicated it may file complaints with the European Commission regarding potential single market violations.

Greek Agricultural Hemp Producers

Hemp farmers in regions like Thessaly, Macedonia, and Thrace face significant economic impact from the retail ban. These producers expanded cultivation specifically for cannabinoid extraction markets, investing in specialized genetics, processing equipment, and quality control systems. With domestic retail markets eliminated, farmers must rely entirely on export markets or pivot to fiber and seed production, which typically generates lower revenues per hectare. Agricultural cooperatives have requested government support programs to offset losses and facilitate market transitions.

Legal and Regulatory Framework

The Greek retail ban operates within a complex legal environment spanning EU regulations, Greek national law, and international drug control treaties. At the EU level, hemp containing up to 0.3% THC is excluded from drug control frameworks under Regulation (EC) No 1672/2000 and subsequent amendments. The European Court of Justice's 2020 Kanavape decision (Case C-663/18) established that CBD derived from legally grown hemp cannot be classified as a narcotic drug under the 1961 UN Single Convention, and member states cannot prohibit such products without specific public health justifications meeting proportionality requirements. EU Novel Food Regulation (EU) 2015/2283 governs cannabinoid products as food supplements. CBD and other cannabinoids require Novel Food authorization before marketing, though enforcement has been inconsistent across member states. Many products currently on the market lack formal Novel Food authorization, creating legal ambiguity that Greece's ban partially addresses by removing products from commerce entirely rather than enforcing Novel Food compliance. Greek national law includes Law 4523/2018, which established the medical cannabis framework. This law permits licensed cultivation and processing for pharmaceutical purposes but does not explicitly address retail sales of hemp-derived products. The May 2026 retail ban derives authority from the Ministry of Health's regulatory powers under Law 3459/2006 concerning pharmaceutical products and public health protection. The government argues that cannabinoid products fall within pharmaceutical regulatory scope regardless of hemp origin. Greek drug control law, codified in Law 4139/2013, criminalizes cannabis possession, cultivation, and distribution outside authorized medical or industrial contexts. Penalties include imprisonment ranging from 5-20 years for trafficking and up to 5 years for possession, though courts often impose suspended sentences for small-quantity personal possession. The retail ban effectively brings cannabinoid commerce under drug control enforcement, with retailers potentially facing criminal charges rather than merely administrative penalties. The interaction between Greek law and EU law creates potential conflicts. Under the principle of EU law supremacy established in Costa v ENEL (Case 6/64), EU regulations take precedence over conflicting national laws. If Greek courts or the European Commission determine that the retail ban violates EU single market principles without adequate public health justification, Greece may face infringement proceedings and potential financial penalties. International obligations under the 1961 UN Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances also inform Greek policy. Greece maintains that cannabinoid retail sales potentially violate international treaty obligations by permitting access to psychoactive substances outside medical and scientific channels. However, this interpretation conflicts with the position of many other EU member states that permit CBD retail sales while remaining parties to the same treaties.

Market and Business Implications

The retail ban eliminates an estimated €150-200 million annual market and forces immediate business closures across Greece's cannabinoid sector. The most immediate impact falls on dedicated hemp retail shops, which numbered approximately 300-400 locations nationwide as of early 2026. These businesses, concentrated in Athens, Thessaloniki, Patras, and tourist destinations, face complete revenue elimination with no transition period. Many operators invested €50,000-150,000 per location in inventory, fixtures, and licensing compliance. The 30-day inventory removal deadline provides insufficient time to liquidate stock at non-loss prices, particularly given that export options are limited by product-specific regulations in destination countries. Pharmacies that added CBD products to their offerings face less severe but still significant impacts. Industry estimates suggest 800-1,000 pharmacies sold CBD oils, topicals, and capsules, generating €20,000-50,000 annually per location from cannabinoid products. While these businesses have diversified revenue streams, the ban eliminates a high-margin category that many pharmacies used to attract younger customers and differentiate from competitors. Online retailers face complete operational shutdown for Greek sales. Several Greek e-commerce platforms specialized in cannabinoid products, generating €10-20 million in combined annual revenue. These businesses must either cease operations entirely or pivot to markets outside Greece, requiring new regulatory compliance, logistics infrastructure, and marketing strategies. Cross-border e-commerce from other EU member states into Greece also faces prohibition, though enforcement mechanisms for individual consumer purchases remain unclear. Manufacturing and processing operations confront demand destruction for products destined for Greek retail. Domestic manufacturers who invested in extraction equipment, laboratory testing capabilities, and pharmaceutical-grade processing facilities lose their primary market. Export opportunities exist but require compliance with destination country regulations and face competition from established manufacturers in other EU states. Several Greek processors have announced temporary production suspensions while evaluating market options. The agricultural sector faces indirect but substantial impacts. Hemp cultivation in Greece expanded from approximately 500 hectares in 2020 to an estimated 3,000-4,000 hectares in 2025, driven primarily by cannabinoid extraction demand. With retail markets eliminated, farmers must redirect production toward fiber, seed, or export markets. Fiber and seed applications typically generate €800-1,500 per hectare compared to €3,000-5,000 per hectare for cannabinoid-focused cultivation, creating significant revenue pressure. Some farmers have indicated they will abandon hemp cultivation entirely, returning to traditional crops like wheat, corn, or olives. Investment capital faces write-downs and potential losses. Venture capital and private equity investments in Greek cannabis businesses totaled an estimated €50-100 million between 2020 and 2025. The retail ban eliminates the primary revenue model for most portfolio companies, forcing investors to either write off investments or support pivots to export-focused business models with uncertain viability. Future investment in Greek cannabis businesses appears unlikely until regulatory clarity improves. Employment impacts ripple across the value chain. Direct retail employment of 5,000-8,000 workers faces immediate elimination, with most positions unlikely to transfer to other sectors given specialized product knowledge requirements. Cultivation, processing, and distribution employment of another 10,000-15,000 workers faces significant reduction, though some positions may survive if businesses successfully pivot to export markets or medical cannabis supply chains. The ban also affects Greece's positioning in the broader European cannabis market. Prior to the prohibition, Greece was emerging as a Mediterranean cultivation hub with potential cost advantages over Northern European producers. The retail ban signals regulatory instability that may deter international investment even in medical cannabis and export-oriented operations, as investors question whether Greece will maintain consistent policy frameworks.

What Experts Say

Legal scholars, industry analysts, and public health experts offer sharply divergent assessments of Greece's retail ban, reflecting broader debates about cannabis regulation across Europe. Professor Maria Kostarelou of the University of Athens Faculty of Law argues the ban likely violates EU single market principles. According to Kostarelou, the Kanavape decision established that member states cannot prohibit CBD products without specific, evidence-based public health justifications meeting proportionality tests. She notes that Greece has not published scientific studies demonstrating that retail CBD sales pose health risks sufficient to justify market exclusion, and the blanket prohibition appears disproportionate compared to regulatory alternatives like licensing, testing requirements, or age restrictions. Dr. Yannis Stefanidis, a public health researcher at the National School of Public Health in Athens, supports the ban from a precautionary principle perspective. Stefanidis points to limited long-term safety data for CBD products, particularly regarding drug interactions, effects on developing brains, and impacts of chronic high-dose consumption. He argues that until comprehensive safety studies establish appropriate use parameters, restricting cannabinoid access to medical channels with physician oversight represents prudent public health policy. Cannabis industry analyst Eleni Papadimitriou of European Cannabis Holdings describes the ban as economically destructive and strategically counterproductive. According to Papadimitriou, the prohibition eliminates legal market participants while creating incentives for black market activity. She notes that consumer demand for cannabinoid products will not disappear due to regulatory changes, and the ban simply redirects commerce to unregulated channels without quality controls or tax revenue generation. Papadimitriou argues that Greece's approach contrasts unfavorably with regulatory models in Switzerland, the Netherlands, and Czech Republic, where licensing frameworks address safety concerns while preserving legal markets. Professor Dimitris Kalogeropoulos, a pharmacologist at Aristotle University of Thessaloniki, emphasizes the distinction between pharmaceutical-grade medical cannabis and retail hemp products. Kalogeropoulos argues that products making therapeutic claims should meet pharmaceutical regulatory standards, including clinical trials, standardized dosing, and physician oversight. He supports the retail ban while advocating for expanded medical cannabis access, arguing this approach better protects consumers while ensuring appropriate therapeutic use. European hemp industry consultant Andreas Weber characterizes Greece's ban as an outlier in European cannabis policy trends. Weber notes that most EU member states are moving toward regulatory frameworks that permit retail sales with quality controls rather than prohibition. He argues that Greece's approach creates competitive disadvantages for Greek businesses while failing to address legitimate regulatory concerns that could be managed through testing requirements, labeling standards, and marketing restrictions.

What's Next

The Greek retail ban faces legal challenges, potential EU intervention, and uncertain enforcement dynamics that will shape cannabis policy across Southern Europe. The most immediate development will be legal challenges in Greek administrative courts. The Greek Cannabis Industry Association has announced plans to file suit seeking suspension of the ban pending full judicial review. These cases will likely argue that the prohibition violates constitutional protections for commercial activity, exceeds ministerial authority, and conflicts with EU law. Greek administrative courts could issue preliminary injunctions suspending the ban if they find substantial legal questions, though such relief appears uncertain given judicial deference to public health regulations. Parallel proceedings at the EU level appear likely. Industry groups have indicated they will file complaints with the European Commission regarding potential single market violations. The Commission must investigate such complaints and can initiate infringement proceedings if it determines Greece has violated EU law. This process typically takes 12-24 months, involving formal notice, Greek government response, and potential referral to the European Court of Justice. If the Commission sides with industry complainants, Greece could face financial penalties and mandatory policy changes. Enforcement of the retail ban will test Greek regulatory capacity. With thousands of retail locations affected and limited resources for comprehensive inspections, authorities must prioritize enforcement targets. Initial indications suggest focus on dedicated hemp shops and high-profile retailers rather than small pharmacies or online sellers. However, inconsistent enforcement could create competitive distortions and legal challenges based on discriminatory application. The ban's impact on black market activity will emerge over coming months. Consumer demand for cannabinoid products will not disappear due to regulatory changes, creating opportunities for illicit suppliers. If unregulated products proliferate, the ban may ultimately worsen the public health concerns it purports to address by eliminating quality-controlled legal alternatives. Monitoring black market trends will be essential for evaluating policy effectiveness. Greece's medical cannabis program may expand to partially offset retail market elimination. The Ministry of Health has indicated willingness to add qualifying conditions and streamline physician authorization processes. If medical access expands significantly, some consumer demand may shift to legal medical channels, though this requires physician participation and patient willingness to engage medical systems for products previously available over-the-counter. Regional policy dynamics will influence Greece's approach. If neighboring countries like Italy, Cyprus, or Bulgaria maintain or expand retail cannabinoid markets, competitive pressures may force Greek policy reconsideration. Cross-border shopping and tourism impacts could create economic incentives for regulatory alignment with regional norms. The broader European cannabis policy landscape continues evolving, with Germany's adult-use legalization framework, Malta's personal cultivation model, and Switzerland's pilot programs creating diverse regulatory approaches. Greece's prohibition positions it as an outlier in European trends, potentially creating pressure for policy reconsideration if other Southern European nations adopt more permissive frameworks. Industry restructuring will continue throughout 2026-2027. Businesses that survive the initial shock will likely pivot toward export markets, medical cannabis supply chains, or complete exit from cannabinoid commerce. Consolidation appears likely, with stronger operators potentially acquiring distressed assets at discounted prices. The ultimate shape of Greece's cannabis industry will depend on whether regulatory frameworks stabilize or continue shifting unpredictably.

Further Reading

• European Court of Justice, Case C-663/18 (Kanavape decision) - Full text available at https://curia.europa.eu
• Greek Law 4523/2018 on Medical Cannabis - Official text in Greek Government Gazette
• EU Regulation 2015/2283 on Novel Foods - Full text at https://eur-lex.europa.eu
• European Industrial Hemp Association policy positions - https://eiha.org
• Greek Ministry of Health press releases on cannabis policy - https://www.moh.gov.gr
• Hellenic National Organization for Medicines market surveillance reports - https://www.eof.gr
• 1961 UN Single Convention on Narcotic Drugs - Full text at https://www.unodc.org
• European Commission infringement procedures database - https://ec.europa.eu/atwork/applying-eu-law/infringements-proceedings
• Greek Cannabis Industry Association statements - Industry trade publications
• Academic research on CBD safety and efficacy - PubMed database at https://pubmed.ncbi.nlm.nih.gov